The headline EPS miss is noise from a non-cash impairment; the core results and raised guidance are the real signal. Traders should focus on the 11% core EPS growth and the raised full-year outlook for core operating margin (+90 to +190 bps) and core EPS growth (+12% to +15%). The $1.5B buyback authorization provides downside support. Monitor the Q3 2026 earnings call for updates on tariff refund realization and the PowerVision discontinuation's impact on R&D spend.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $75.35entry
- T+1 · 3mo ago −2.35%α −2.60% · $73.58
- T+5 · 3mo ago −2.39%α −1.99% · $73.55
- T+20 · 2mo ago −9.18%α −8.12% · $68.43
- T+60 · 13d ago +2.60%α +3.09% · $77.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alcon reported Q2 2026 net sales of $2.8 billion, up 8% YoY (7% constant currency), driven by strong performance across Surgical and Vision Care segments. However, reported operating income collapsed to $11 million (from $247 million) and diluted EPS was $0.00 due to a $505 million non-cash impairment charge from discontinuing the PowerVision IOL programs. Core diluted EPS (non-IFRS) rose 11% to $0.84, and the company raised its full-year guidance for core operating margin and core diluted EPS growth, signaling underlying operational strength despite the one-time charge. The market should focus on the core results and raised guidance, which are positive, while the impairment is a non-cash item that does not affect cash flow or long-term objectives.
Key Facts
- Q2 2026 net sales of $2.8 billion, up 8% reported / 7% constant currency vs Q2 2025
- Reported diluted EPS of $0.00 vs $0.35 in Q2 2025, due to a $505 million non-cash impairment charge from discontinuing PowerVision IOL programs
- Core diluted EPS (non-IFRS) of $0.84, up 11% vs Q2 2025
- Core operating margin improved 150 bps to 20.6% (reported) / 160 bps (constant currency)
- Full-year 2026 guidance raised: core operating margin change now +90 to +190 bps (from +70 to +170 bps); core diluted EPS growth now +12% to +15% (from +10% to +13%)
- Net cash from operations of $928 million in H1 2026, up from $889 million in H1 2025
- Free cash flow of $693 million in H1 2026, up from $681 million
- Returned $538 million to shareholders YTD through dividends and share repurchases
- $1.5 billion share repurchase authorization approved in May 2026, with ~$1.2 billion remaining
- Terminated proposed acquisition of LENSAR, Inc. on March 16, 2026
Financial Impact
Q2 2026 net sales $2.8B (+8% YoY); reported operating income $11M (vs $247M); core operating income $574M (+17%); reported diluted EPS $0.00 (vs $0.35); core diluted EPS $0.84 (+11%); H1 2026 operating cash flow $928M (+$39M YoY); free cash flow $693M (+$12M YoY)
Risk Factors
- Tariff impact of $40M-$90M expected for FY 2026, with ongoing uncertainty from U.S. trade policy
- PowerVision program discontinuation may signal broader R&D pipeline risk or future impairment charges
- Continued softness in the cataract market could pressure Surgical consumables growth
- Foreign currency volatility could impact reported results, with expected +90 bps tailwind to sales growth in FY 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001167379-26-000030 |
| Document: q22026pressrelease.htm | 0001167379-26-000030 |
| Document: alc-20260630.htm | 0001167379-26-000030 |
| Document: 0001167379-26-000030-index-headers.html | 0001167379-26-000030 |
| Document: 0001167379-26-000030-index.html | 0001167379-26-000030 |
| Document: 0001167379-26-000030.txt | 0001167379-26-000030 |
Track record
5 reports on ALC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $72.46 Now $73.64 +1.63% settles Feb 9
- Nov 6, 202610d ago Institutional Cluster Mixed 3/10 Entry $74.94 Now $73.64 −1.73% settles Feb 4
- Aug 10, 202614w ago 6-K Bullish 6/10 Viewing Entry $75.35 to $77.31 Now $73.64 −2.27% ▲ +2.60% +3.09% vs SPY
- Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.61 to $65.39 Now $73.64 +8.92% ▼ −3.28% −6.90% vs SPY
- Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.80 to $64.87 Now $73.64 +8.61% ▼ −4.32% −8.81% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers